Filing Details

Accession Number:
0001628280-24-023613
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-05-15 16:39:03
Reporting Period:
2024-05-13
Accepted Time:
2024-05-15 16:39:03
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1104506 Insmed Inc INSM Pharmaceutical Preparations (2834) 541972729
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1930805 Drayton John Wise 700 Us Highway 202/206
Bridgewater NJ 08807
Chief Commercial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-05-13 14,518 $0.00 128,347 No 4 A Direct
Common Stock Disposition 2024-05-14 5,088 $25.47 123,259 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Acquisiton 2024-05-13 71,160 $0.00 71,160 $25.83
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
71,160 2034-05-13 No 4 A Direct
Footnotes
  1. Represents Restricted Stock Units (RSUs), each representing a contingent right to receive one share of Common Stock, granted pursuant to the Company's Amended and Restated 2019 Incentive Plan, as amended. The RSUs vest as follows: 25% percent on the first day of the first month following the first anniversary of the date of grant (the Initial Vesting Date) and 25% on each anniversary of the Initial Vesting Date until fully vested.
  2. Each RSU was granted on May 13, 2024 for no consideration.
  3. Shares sold to satisfy withholding tax obligations upon the vesting of RSUs and to cover related broker fees.
  4. This is the weighted average sales price representing 5,088 shares sold at prices ranging from $25.45 to $25.50 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
  5. These stock options were granted under the Company's Amended and Restated 2019 Incentive Plan, as amended. The options become exercisable based on the following vesting schedule: 25% vest on the Initial Vesting Date and an additional 12.5% vest every six months thereafter through the fourth anniversary of the Initial Vesting Date.